Skip to main content
SpringerLink
Log in

Prebiotics and Probiotics in Inflammatory Bowel Disease (IBD)

  • Chapter
  • First Online:
Nutritional Management of Inflammatory Bowel Diseases

Abstract

Modifying the microbiome as a therapeutic strategy in inflammatory bowel disease (IBD) through the use of probiotics and prebiotics makes theoretical sense as current evidence indicates a fundamental role for luminal bacteria in the pathophysiology of IBD. Clinical studies, however, have not, to date, realized this promise. There is no substantial evidence to support the use of prebiotics or probiotics in Crohn’s disease. Studies in ulcerative colitis are conflicting but suggest potential value in some clinical contexts where a trend toward clinical benefit has been seen. Prebiotics may improve quality of life but not influence more traditional clinical end points. However, the most convincing evidence for the use of probiotics in IBD is in pouchitis where benefits in both primary prevention and maintenance of remission have been demonstrated. Several limitations limit the interpretation of most all studies performed to date: small size of study populations, heterogeneity of strains, dosing and formulations as well as a failure to account for important confounders such as concurrent medications, and diet; these deficiencies provide the impetus for future well-designed and adequately powered studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bamias G, Nyce MR, De La Rue SA, Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med. 2005;143:895–904.

    Article  CAS  PubMed  Google Scholar 

  2. Onderdonk AB, Franklin ML, Cisneros RL. Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora. Infect Immun. 1981;32:225–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Sartor RB. Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implications. In: Sartor RB, Snadborn WJ, editors. Kirsner’s inflammatory bowel diseases. Philadelphia: Elsevier; 2004. p. 138–62.

    Google Scholar 

  5. Moran JP, Walter J, Tannock GW, Tonkonogy SL, Sartor RB. Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin-10 deficient mice. Inflamm Bowel Dis. 2009;15:1022–31.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Bothin C, Midtvedt T. The role of gastrointestinal microflora in postsurgical adhesion formation—a study in germfree rats. Eur Surg Res. 1992;24:309–12.

    Article  CAS  PubMed  Google Scholar 

  7. Mourelle M, Salas A, Guarner F, et al. Stimulation of transforming growth factor beta1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology. 1998;114:519–26.

    Article  CAS  PubMed  Google Scholar 

  8. Van Tol EAF, Holt L, Ling Li F, et al. Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts. Am J Physiol. 1999;277:G245–55.

    PubMed  Google Scholar 

  9. Rigby RJ, Hunt MR, Scull BP, et al. A new animal model of postsurgical bowel inflammation and fibrosis: the effect of commensal microflora. Gut. 2009;58:1104–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Shanahan F. The colonic microbiota in health and disease. Curr Opin Gastroenterol. 2013;29:49–54.

    Article  CAS  PubMed  Google Scholar 

  11. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in nod2 associated with susceptibility to Crohn’s disease. Nature. 2001;411:603–6.

    Article  CAS  PubMed  Google Scholar 

  12. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44–54.

    Article  PubMed  Google Scholar 

  13. Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon. Gut. 2003;52:237–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut. 2011;60:631–7.

    Article  PubMed  Google Scholar 

  15. Ruseler-van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut. 1994;35:658–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. D'Haens GR, Geboes K, Peeters M, et al. P: early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262–7.

    Article  PubMed  Google Scholar 

  17. Rath H, Ikeda J, Wilson K, Sartor R. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology. 1999;116:310–9.

    Article  CAS  PubMed  Google Scholar 

  18. Neut C, Bulois P, Desreumaux P, Membre JM, Lederman E, Gambiez L, Cortot A, Quandalle P, van Kruiningen H, Colombel JF. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn’s disease. Am J Gastroenterol. 2002;97:939–46.

    Article  PubMed  Google Scholar 

  19. Quigley E. Commensal bacteria: the link between IBS and IBD? Curr Opin Clin Nutr Metab Care. 2011;14:497–503.

    Article  PubMed  Google Scholar 

  20. Biedermann L, Zeitz J, Mwinyi J, Sutter-Minder E, Rehman A, Ott SJ, et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS One. 2013;8:e59260.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009;137:1716–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Murphy EF, Cotter PD, Healy S, Marques TM, O’Sullivan O, Fouhy F, et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut. 2010;59:1635–42.

    Article  CAS  PubMed  Google Scholar 

  23. Montenegro L, Losurdo G, Licinio R, Zamparella M, Giorgio F, Ierardi E, et al. Non steroidal anti-inflammatory drug induced damage on lower gastro-intestinal tract: is there an involvement of microbiota? Curr Drug Saf. 2014;9:196–204.

    Article  CAS  PubMed  Google Scholar 

  24. Hviid A, Svanström H, Frisch M. Antibiotic use in inflammatory bowel diseases in childhood. Gut. 2011;60:49–54.

    Article  PubMed  Google Scholar 

  25. Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and noninflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011;11:7.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Sartor RB. Key questions to guide a better understanding of host-commensal microbiota interactions in intestinal inflammation. Mucosal Immunol. 2011;4:127–32.

    Article  CAS  PubMed  Google Scholar 

  27. Ungaro R, Bernstein CN, Gearry R, Hviid A, Kolho KL, Kronman MP, et al. Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol. 2014;109:1728–38.

    Article  CAS  PubMed  Google Scholar 

  28. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401–12.

    CAS  PubMed  Google Scholar 

  29. Walker AW, Duncan SH, McWilliam Leitch EC, Child MW, Flint HJ. pH and peptide supply can radically alter bacterial populations and short-chain fatty acid ratios within microbial communities from the human colon. Appl Environ Microbiol. 2005;71:3692–700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Koleva PT, Valcheva RS, Sun X, Gänzle MG, Dieleman LA. Inulin and fructo-oligosaccharides have divergent effects on colitis and commensal microbiota in HLA-B27 transgenic rats. Br J Nutr. 2012;108(9):1633–43.

    Article  CAS  PubMed  Google Scholar 

  31. Looijer-van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis. 2009;15:454–62.

    Article  PubMed  Google Scholar 

  32. Nishimura T, Andoh A, Hashimoto T, Kobori A, Tsujikawaand T, Fujiyama Y. J Clin Biochem Nutr. 2010;46:105–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Guarner F. Inulin and oligofructose: impact on intestinal diseases and disorders. Br J Nutr. 2005;93 Suppl 1:S61–5.

    Article  CAS  PubMed  Google Scholar 

  34. Howarth GS, Wang H. Role of endogenous microbiota, probiotics and their biological products in human health. Nutrients. 2013;5:58–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. FAO/WHO. Guidelines for the evaluation of probiotics in food. Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. London (Ontario, Canada): World Health Organization; 2002.

    Google Scholar 

  36. Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology. 2014;146(6):1554–63.

    Article  PubMed  Google Scholar 

  37. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res. 1992;32:141–4.

    Article  CAS  PubMed  Google Scholar 

  38. Ogawa T, Asai Y, Tamai R, Makimura Y, Sakamoto H, Hashikawa S, Yasuda K. Natural killer cell activities of synbiotic Lactobacillus casei ssp. casei in conjunction with dextran. Clin Exp Immunol. 2006;143:103–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Petrof EO, Kojima K, Ropeleski MJ, Musch MW, Tao Y, De Simone C, et al. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology. 2004;127:1474–87.

    Article  CAS  PubMed  Google Scholar 

  40. Di Marzio L, Russo FP, D’Alo S, Biordi L, Ulisse S, Amico-sante S, et al. Apoptotic effects of selected strains of lactic acid bacteria on a human T leukemia cell line are associated with bacterial arginine deiminase and/or sphingomyelinase activities. Nutr Cancer. 2001;40:185–96.

    Article  PubMed  Google Scholar 

  41. Maassen CB, van Holten-Neelen C, Balk F, den Bak-Glashouwer MJ, Leer RJ, Laman JD, et al. Strain- dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine. 2000;18:2613–23.

    Article  CAS  PubMed  Google Scholar 

  42. Morita H, He F, Fuse T, Ouwehand AC, Hashimoto H, Hosoda M, et al. Adhesion of lactic acid bacteria to caco-2 cells and their effect on cytokine secretion. Microbiol Immunol. 2002;46:293–7.

    Article  CAS  PubMed  Google Scholar 

  43. Ma D, Forsythe P, Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun. 2004;72:5308–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. West CE, Jenmalm MC, Prescott SL. The gut microbiota and its role in the development of allergic disease: a wider perspective. Clin Exp Allergy. 2015;45(1):43–53.

    Article  CAS  PubMed  Google Scholar 

  45. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extra- cellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52:827–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem. 2002;277:50959–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev. 2004;28:405–40.

    Article  CAS  PubMed  Google Scholar 

  48. Collado MC, Surono IS, Meriluoto J, Salminen S. Potential probiotic characteristics of lactobacillus and enterococcus strains isolated from traditional dadih fermented milk against pathogen intestinal colonization. J Food Prot. 2007;70:700–5.

    PubMed  Google Scholar 

  49. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126(6):1620–33.

    Article  PubMed  Google Scholar 

  50. Shiba T, Aiba Y, Ishikawa H, Ushiyama A, Takagi A, Mine T, Koga Y. The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. Microbiol Immunol. 2003;47:371–8.

    Article  CAS  PubMed  Google Scholar 

  51. Kuhbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, Kleessen B, Gionchetti P, Blaut M, Campieri M, Folsch UR, Kamm MA, Schreiber S. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut. 2006;55:833–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Ewaschuk JB, Walker JW, Diaz H, Madsen KL. Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. J Nutr. 2006;136:1483–7.

    CAS  PubMed  Google Scholar 

  53. Whelan K, Myers CE. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr. 2010;91(3):687–703. doi:10.3945/ajcn.2009.28759.

    Article  CAS  PubMed  Google Scholar 

  54. Grimoud J, Durand H, de Souza S, Monsan P, Ouarné F, Theodorou V, Roques C. In vitro screening of probiotics and synbiotics according to anti-inflammatory and anti-proliferative effects. Int J Food Microbiol. 2010;144(1):42–50.

    Article  CAS  PubMed  Google Scholar 

  55. Benjamin JL, Hedin CR, Koutsoumpas A, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut. 2011;60(7):923–9.

    Article  CAS  PubMed  Google Scholar 

  56. Hafer A, Krämer S, Duncker S, Krüger M, Manns MP, Bischoff SC. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol. 2007;7:36.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr. 2000;31:453–7.

    Article  CAS  PubMed  Google Scholar 

  58. Fujimori S, Tatsuguchi A, Gudis K, et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn’s disease. J Gastroenterol Hepatol. 2007;22:1199–204.

    Article  PubMed  Google Scholar 

  59. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus gg in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol. 2004;4:5.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of lactobacillus gg versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis. 2005;11:833–9.

    Article  PubMed  Google Scholar 

  61. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2006;CD004826.

    Google Scholar 

  62. Rahimi R, Nikfar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease. Dig Dis Sci. 2008;53:2524–31.

    Article  PubMed  Google Scholar 

  63. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea—a pilot study. Z Gastroenterol. 1993;31(2):129–34.

    CAS  PubMed  Google Scholar 

  64. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci. 2000;45(7):1462–4.

    Article  CAS  PubMed  Google Scholar 

  65. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn’s disease in remission. Scand J Gastroenterol. 2008;43(7):842–8.

    Article  PubMed  CAS  Google Scholar 

  66. Bourreille A, Cadiot G, Le Dreau G, FLORABEST Study Group, et al. Saccharomyces boulardii does not prevent relapse of Crohn’s disease. Clin Gastroenterol Hepatol. 2013;11(8):982–7.

    Article  PubMed  Google Scholar 

  67. Malchow HA. Crohn’s disease and Escherichia coli: a new approach to therapy to maintain remission of colonic Crohn’s disease. J Clin Gastroenterol. 1997;25:653–8.

    Article  CAS  PubMed  Google Scholar 

  68. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of lactobacillus johnsonii la1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55:842–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized controlled clinical trial of probiotics (lactobacillus johnsonii, la1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis. 2007;13:135–42.

    Article  PubMed  Google Scholar 

  70. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC, Forbes A. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease. Gut. 2006;55:348–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Steed H, Macfarlane GT, Blackett KL, et al. Clinical trial: the microbiological and immunological effects of synbiotic consumption—a randomized double-blind placebo-controlled study in active Crohn’s disease. Aliment Pharmacol Ther. 2010;32(7):872–83.

    Article  CAS  PubMed  Google Scholar 

  72. Rutgeerts P, D’Haens G, Baert F, et al. Randomized placebo controlled trial of pro and prebiotics (synbiotics cocktail) for maintenance of infliximab induced remission of luminal Crohn’s disease. Gastroenterology. 2004;126:A467.

    Google Scholar 

  73. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473–87.

    PubMed  PubMed Central  Google Scholar 

  74. Bamba T, Kanauchi O, Andoh A, Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol. 2002;17(8):818–24.

    Article  CAS  PubMed  Google Scholar 

  75. Kanauchi O, Suga T, Tochihara M, et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol. 2002;37(14):67–72.

    Article  CAS  PubMed  Google Scholar 

  76. Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol. 1991;26(7):747–50.

    Article  CAS  PubMed  Google Scholar 

  77. Casellas F, Borruel N, Torrej A, et al. Oral oligofructose enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther. 2007;25(9):1061–7.

    Article  CAS  PubMed  Google Scholar 

  78. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;(4):CD005573

    Google Scholar 

  79. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(11):1202–9.

    Article  PubMed  Google Scholar 

  80. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105(10):2218–27.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (vsl#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437–43.

    Article  CAS  PubMed  Google Scholar 

  82. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20(10):1133–41.

    Article  CAS  PubMed  Google Scholar 

  83. Petersen A, Mirsepasi H, Halkjaer S, et al. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double blind randomized placebo controlled clinical trial. J Crohns Colitis. 2014;8(11):1498–505.

    Article  PubMed  Google Scholar 

  84. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med. 2010;10:13.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012;35(3):327–34.

    Article  CAS  PubMed  Google Scholar 

  86. Zigra PI, Maipa VE, Alamanos YP. Probiotics and remission of ulcerative colitis: a systematic review. Neth J Med. 2007;65:411–8.

    CAS  PubMed  Google Scholar 

  87. Shanahan F, Collins SM. Pharmabiotic manipulation of the microbiota in gastrointestinal disorders, from rationale to reality. Gastroenterol Clin North Am. 2010;39:721–6.

    Article  PubMed  Google Scholar 

  88. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis. 2011;5(2):115–21. doi:10.1016/j.crohns.2010.11.004.

    Article  PubMed  Google Scholar 

  89. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853–8.

    Article  CAS  PubMed  Google Scholar 

  90. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635–9.

    Article  CAS  PubMed  Google Scholar 

  91. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic escherichia coli nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(11):1567–74.

    Article  CAS  PubMed  Google Scholar 

  93. Huynh HQ, deBruyn J, Guan L, et al. Probiotic preparation vsl#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2009;15:760–8.

    Article  PubMed  Google Scholar 

  94. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2011;12:CD007443

    Google Scholar 

  95. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O’Neil A, Macfarlane GT. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54:242–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Fujimori S, Gudis K, Mitsui K, et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition. 2009;25(5):520–5.

    Article  PubMed  Google Scholar 

  97. Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 1961;30:393–407.

    CAS  PubMed  Google Scholar 

  98. Ishikawa H, Matsumoto S, Ohashi Y, et al. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion. 2011;84(2):128–33.

    Article  PubMed  Google Scholar 

  99. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994;107:1856–60.

    CAS  PubMed  Google Scholar 

  100. Calabrese C, Fabbri A, Gionchetti P, et al. Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. Aliment Pharmacol Ther. 2007;25(11):1311–6.

    Article  CAS  PubMed  Google Scholar 

  101. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003;17(4):509–15.

    Article  CAS  PubMed  Google Scholar 

  102. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305–9.

    Article  CAS  PubMed  Google Scholar 

  103. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124(5):1202–9.

    Article  PubMed  Google Scholar 

  104. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53(1):108–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis. 2008;14(5):662–8.

    Article  PubMed  Google Scholar 

  106. Veerappan GR, Betteridge J, Young PE. Probiotics for the treatment of inflammatory bowel disease. Curr Gastroenterol Rep. 2012;14:324–33.

    Article  PubMed  Google Scholar 

  107. McLaughlin SD, Walker AW, Churcher C, et al. The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing. Ann Surg. 2010;252:90–8.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Welters CFM, Heineman E, Thunnissen FBJM, van den Bogaard AEJM, Soeters PB, Baeten CGMI. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum. 2002;45:621–7.

    Article  PubMed  Google Scholar 

  109. Guenther K, Straube E, Pfister W, et al. Severe sepsis after probiotic treatment with Escherichia coli NISSLE 1917. Pediatr Infect Dis J. 2010;29:188–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Fondren Inflammatory Bowel Disease Program, Lynda K and David M Underwood Center for Digestive Disorders, 6550 Fannin St. SM 1001, Houston, TX, 77030, USA

    Bincy P. Abraham M.D., M.S., F.A.C.P. & Eamonn M. M. Quigley MD, FRCP, FACP, FACG, FRCPI

Authors
  1. Bincy P. Abraham M.D., M.S., F.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eamonn M. M. Quigley MD, FRCP, FACP, FACG, FRCPI
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bincy P. Abraham M.D., M.S., F.A.C.P. .

Editor information

Editors and Affiliations

  1. Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA

    Ashwin N. Ananthakrishnan

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Abraham, B.P., Quigley, E.M.M. (2016). Prebiotics and Probiotics in Inflammatory Bowel Disease (IBD). In: Ananthakrishnan, A. (eds) Nutritional Management of Inflammatory Bowel Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-26890-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26890-3_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26888-0

  • Online ISBN: 978-3-319-26890-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation